---
title: "GE HealthCare Technologies Non-GAAP EPS of $1.45 beats by $0.19, revenue of $5.31B misses by $20M"
date: "2025-02-13 14:21:46"
summary: "GE HealthCare Technologies press release (NASDAQ:GEHC): Q4 Non-GAAP EPS of $1.45 beats by $0.19. Revenue of $5.31B (+2.1% Y/Y) misses by $20M. Revenues of $5.3 billion increased 2% on both a reported and Organic* basis year-over-year. Revenue growth was driven by Advanced Visualization Solutions (AVS) and Pharmaceutical Diagnostics (PDx), with..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* GE HealthCare Technologies [press release](https://seekingalpha.com/pr/20001107-ge-healthcare-reports-fourth-quarter-and-full-year-2024-financial-results) (NASDAQ:[GEHC](https://seekingalpha.com/symbol/GEHC "GE HealthCare Technologies Inc.")): Q4 Non-GAAP EPS of $1.45  beats by $0.19.
* Revenue of $5.31B (+2.1% Y/Y)  misses by $20M.
* Revenues of $5.3 billion increased 2% on both a reported and Organic\* basis year-over-year. Revenue growth was driven by Advanced Visualization Solutions ([AVS](https://seekingalpha.com/symbol/AVS "Direxion Shares ETF Trust - Direxion Daily AVGO Bear 1X Shares")) and Pharmaceutical Diagnostics (PDx), with overall strength in the U.S.
* Total company book-to-bill was 1.09 times. Total company orders increased 6% organically year-over-year.
* 2025 guidance is as follows:
  
  + Organic revenue growth of 2% to 3% year-over-year, which reflects continued demand for our products and services as well as a measured view of market conditions in China
  + Adjusted EBIT margin of 16.7% to 16.8%, reflecting an expansion of approximately 40 to 50 basis points versus 2024 Adjusted EBIT margin\* of 16.3%
  + Adjusted effective tax rate ([ETR](https://seekingalpha.com/symbol/ETR "Entergy Corporation")) in the range of 22% to 23%
  + Adjusted EPS in the range of $4.61 to $4.75 vs. $4.65 consensus representing 3% to 6% growth versus Adjusted EPS\* of $4.49 for 2024
  + Free cash flow of at least $1.75 billion

[seekalpha](https://seekingalpha.com/news/4407537-ge-healthcare-technologies-non-gaap-eps-of-1_45-beats-by-0_19-revenue-of-5_31b-misses-by-20m)
